Explain this page
Arphra AIPlain-English read on Acadia Healthcare Company, Inc.’s valuationRatios & metrics
Profitability, returns on capital, growth, and credit — all derived from the historical income statement, balance sheet, and cash flow rows in our data warehouse.
Quality composite
BSolid
A snapshot of the latest fiscal year’s margins, returns on capital, balance-sheet strength and efficiency, computed from the income statement, balance sheet and cash-flow rows. Source income / balance / cash_flow.
Profitability
Gross margin17.6%
Operating margin11.7%
Net margin-33.3%
ROE-51.5%
ROA-20.0%
ROIC8.5%
Liquidity & leverage
Current ratio1.55×
Quick ratio1.54×
Debt / equity1.24×
Net debt / EBITDA-3.42×
Interest coverage3×
Efficiency & per-share
Asset turnover0.60×
Inventory days1
Days sales out.60
FCF / share$-4.85
Book value / share$23.60
Valuation multiples
Price- and EV-based multiples plus shareholder yields. Snapshot at each fiscal year-end from key_metrics (FMP).
ActualEstimate
| In USD | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|---|---|
| Headline | |||||||||
| Market cap | — | — | — | $3.63B | $1.29B | — | — | — | — |
| Enterprise value | — | — | — | $5.64B | $3.81B | — | — | — | — |
| Multiples | |||||||||
| P / E | — | — | — | — | — | — | — | — | — |
| P / B | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / Sales | — | — | — | 1.79 | 1.15 | — | — | — | — |
| EV / FCF | — | — | — | -10.06 | -8.66 | — | — | — | — |
| Yields | |||||||||
| Earnings yield | — | — | — | +7.04% | -85.68% | — | — | — | — |
| Free cash flow yield | — | — | — | -15.43% | -34.18% | — | — | — | — |
| Dividend yield | — | — | — | — | — | — | — | — | — |
Profitability
Margin structure across the last 5 fiscal years
ActualEstimate
| In USD | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|---|---|
| Margins | |||||||||
| Gross margin | +96.08% | +96.16% | +23.31% | +22.57% | +17.61% | +20.73% | +21.37% | +21.00% | +21.01% |
| Operating margin | +17.91% | +17.92% | +17.30% | +16.56% | +11.71% | +15.32% | +14.84% | +15.32% | +15.52% |
| EBITDA margin | +19.85% | +21.52% | +6.46% | +19.27% | -22.27% | +15.12% | +14.98% | +15.02% | +14.93% |
| EBIT margin | +15.24% | +17.01% | +1.94% | +14.53% | -27.98% | -3.87% | -3.95% | -3.92% | -3.83% |
| Pre-tax margin | +11.91% | +14.33% | -0.87% | +10.84% | -32.18% | -7.41% | -7.41% | -7.42% | -7.40% |
| Net margin | +8.24% | +10.46% | -0.74% | +8.10% | -33.29% | -8.45% | -8.68% | -8.74% | -8.53% |
| Cost structure | |||||||||
| Cost of revenue / sales | +3.92% | +3.84% | +76.69% | +77.43% | +82.39% | +76.74% | +76.94% | +81.11% | +80.41% |
| R&D intensity | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A intensity | +61.31% | +61.17% | +6.01% | +6.01% | +5.90% | +5.90% | +6.03% | +5.97% | +5.81% |
| Effective tax rate | +24.50% | +25.15% | — | +22.64% | — | — | — | — | — |
Returns on capital
ROE / ROA / ROC / ROIC over the relevant capital base, plus the 3-step DuPont decomposition of ROE.
ActualEstimate
| In USD | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| Return on equity (ROE) | +7.38% | +9.42% | -0.75% | +8.01% | -51.52% | -9.40% | -10.22% | -9.95% | -9.98% |
| Return on assets (ROA) | +4.00% | +5.48% | -0.40% | +4.29% | -19.95% | -4.76% | -4.88% | -4.73% | -4.75% |
| Return on capital (ROC) | +9.82% | +10.56% | +11.52% | +9.90% | +8.09% | +9.89% | +9.80% | +10.05% | +10.36% |
| Return on invested capital (ROIC) | +4.52% | +6.16% | +8.64% | +4.84% | +6.07% | +7.42% | +7.35% | +7.53% | +7.77% |
| Asset turnover | +48.54% | +52.33% | +54.65% | +52.95% | +59.93% | +56.30% | +56.23% | +54.18% | +55.66% |
| DuPont · ROE decomposition | |||||||||
| Net margin | +8.24% | +10.46% | -0.74% | +8.10% | -33.29% | -8.45% | -8.68% | -8.74% | -8.53% |
| Asset turnover (× revenue / assets) | +48.54% | +52.33% | +54.65% | +52.95% | +59.93% | +56.30% | +56.23% | +54.18% | +55.66% |
| Equity multiplier (× assets / equity) | +184.60% | +171.94% | +185.58% | +186.69% | +258.23% | +197.56% | +209.50% | +210.24% | +210.26% |
Activity & efficiency
Turnover ratios and days-outstanding — how efficiently the business converts assets and working capital into sales and cash.
ActualEstimate
| In USD | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||
| Asset turnover | 0.49 | 0.52 | 0.55 | 0.53 | 0.60 | 0.56 | 0.56 | 0.54 | 0.56 |
| Fixed-asset turnover | 1.21 | 1.25 | 1.23 | 1.06 | 1.02 | — | — | — | — |
| Inventory turnover | 18.95 | 19.70 | 423.80 | 431.90 | 480.01 | — | — | — | — |
| Receivables turnover | 7.60 | 7.38 | 6.82 | 7.47 | 6.08 | — | — | — | — |
| Payables turnover | 0.92 | 0.96 | 14.39 | 10.49 | 18.15 | — | — | — | — |
| Days outstanding | |||||||||
| Days sales outstanding (DSO) | 48.01 | 49.46 | 53.53 | 48.83 | 60.07 | — | — | — | — |
| Days inventory outstanding (DIO) | 19.26 | 18.53 | 0.86 | 0.85 | 0.76 | — | — | — | — |
| Days payables outstanding (DPO) | 396.68 | 381.48 | 25.37 | 34.78 | 20.11 | — | — | — | — |
| Cash conversion cycle | -329.41 | -313.48 | 29.02 | 14.90 | 40.71 | — | — | — | — |
Cash flow quality
How well reported earnings translate into operating and free cash flow, plus reinvestment intensity.
ActualEstimate
| In USD | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|---|---|
| Operating CF / Net income | 1.96 | 1.39 | -21.34 | 0.51 | -0.12 | -0.95 | -0.91 | -0.92 | -0.92 |
| FCF / Net income | 0.68 | 0.31 | -1.76 | -2.19 | 0.40 | 1.16 | 1.15 | 1.16 | 1.15 |
| FCF margin | +5.60% | +3.23% | +1.30% | -17.78% | -13.28% | -9.81% | -10.02% | -10.16% | -9.79% |
| OCF margin | +16.18% | +14.58% | +15.79% | +4.11% | +3.98% | +8.03% | +7.92% | +8.02% | +7.88% |
| CapEx / Revenue | +10.58% | +11.34% | +14.48% | +21.89% | +17.26% | +17.67% | +18.36% | +17.64% | +18.33% |
| CapEx / D&A | 2.29 | 2.51 | 3.20 | 4.62 | 3.02 | — | — | — | — |
| Stock-based comp / Revenue | +1.62% | +1.14% | +1.10% | +1.18% | +0.96% | — | — | — | — |
Per-share & shareholder yield
EPS, book value, sales, cash flow and dividends per share — plus payout / retention.
ActualEstimate
| In USD | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|---|---|
| EPS · diluted | 2.10 | 2.98 | -0.24 | 2.78 | -12.16 | 1.51 | 1.75 | 2.03 | 2.16 |
| EPS · basic | 2.15 | 3.05 | -0.24 | 2.79 | -12.16 | 1.52 | 1.77 | 2.01 | 2.17 |
| Book value / share | 28.45 | 31.69 | 31.75 | 34.66 | 23.60 | 33.56 | 33.77 | 36.54 | 38.97 |
| Tangible BV / share | 3.45 | 6.58 | 6.47 | 9.30 | 8.24 | 33.56 | 33.77 | 36.54 | 38.97 |
| Sales / share | 25.49 | 28.51 | 32.20 | 34.26 | 36.52 | 37.33 | 39.79 | 41.62 | 45.61 |
| Operating CF / share | 4.12 | 4.16 | 5.08 | 1.41 | 1.45 | 3.00 | 3.15 | 3.34 | 3.59 |
| Free cash flow / share | 1.43 | 0.92 | 0.42 | -6.09 | -4.85 | -3.66 | -3.99 | -4.23 | -4.47 |
| Dividends / share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payout ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Retention ratio | +100.00% | +100.00% | +100.00% | +100.00% | +100.00% | +100.00% | +100.00% | +100.00% | +100.00% |
Growth
Year-over-year change for headline P&L lines, plus through-cycle CAGR
ActualEstimate
| In USD | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | 2026E | 2027E | 2028E | 2029E | 8y CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Top-line | ||||||||||
| Revenue · YoY | — | +12.79% | +12.20% | +7.69% | +5.04% | +2.91% | +6.02% | +5.21% | +9.68% | +7.64% |
| Gross profit · YoY | — | +12.88% | -72.81% | +4.30% | -18.05% | +21.15% | +9.29% | +3.37% | +9.76% | -10.99% |
| Profit | ||||||||||
| Operating income · YoY | — | +12.84% | +8.32% | +3.10% | -25.72% | +34.60% | +2.73% | +8.57% | +11.12% | +5.73% |
| EBITDA · YoY | — | +22.24% | -66.33% | +221.42% | -221.38% | +169.86% | +5.03% | +5.49% | +9.03% | +3.87% |
| Net income · YoY | — | +43.28% | -107.93% | +1279.73% | -531.42% | +73.87% | -8.83% | -5.93% | -7.09% | — |
| Operating | ||||||||||
| EBIT · YoY | — | +25.84% | -87.21% | +707.27% | -302.31% | +85.78% | -8.39% | -4.20% | -7.25% | — |
| R&D · YoY | — | — | — | — | — | — | — | — | — | — |
| Per-share | ||||||||||
| EPS · diluted · YoY | — | +41.90% | -108.05% | +1258.33% | -537.41% | +112.40% | +16.05% | +16.23% | +6.23% | +0.35% |
| EPS · basic · YoY | — | +41.86% | -107.87% | +1262.50% | -535.84% | +112.51% | +16.60% | +13.57% | +7.76% | +0.12% |
Credit & leverage
Balance-sheet health + interest coverage + liquidity. Coverage ratios use period-end debt and trailing interest expense.
ActualEstimate
| In USD | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|---|---|
| Leverage | |||||||||
| Total debt | $1.64B | $1.53B | $1.51B | $2.09B | $2.65B | $2.21B | $2.4B | $2.46B | $2.69B |
| Net debt | $1.5B | $1.43B | $1.41B | $2.01B | $2.52B | $2.1B | $2.28B | $2.33B | $2.55B |
| Net debt / EBITDA | 3.27 | 2.55 | 7.46 | 3.31 | -3.42 | 4.08 | 4.22 | 4.08 | 4.09 |
| Debt / equity | 0.63 | 0.53 | 0.52 | 0.65 | 1.24 | 0.72 | 0.78 | 0.74 | 0.75 |
| Debt / assets | +34.36% | +30.67% | +28.19% | +35.01% | +48.03% | +36.56% | +37.39% | +35.04% | +35.84% |
| Equity / assets | +54.17% | +58.16% | +53.89% | +53.57% | +38.73% | +50.62% | +47.73% | +47.57% | +47.56% |
| Coverage | |||||||||
| EBITDA / interest expense | 5.97 | 8.05 | 2.30 | 5.22 | -5.31 | 4.35 | 4.33 | 4.27 | 4.13 |
| Operating income / interest | 5.38 | 6.70 | 6.17 | 4.49 | 2.79 | 4.40 | 4.29 | 4.36 | 4.29 |
| Interest expense | $76.99M | $69.76M | $82.13M | $116.37M | $138.86M | $118.59M | $125.15M | $133.71M | $150.93M |
| Liquidity | |||||||||
| Current ratio | 1.22 | 1.30 | 0.67 | 1.00 | 1.55 | — | — | — | — |
| Quick ratio | 1.08 | 1.16 | 0.60 | 0.86 | 1.29 | — | — | — | — |
| Cash ratio | 0.33 | 0.25 | 0.11 | 0.13 | 0.25 | — | — | — | — |
| Working capital | $90.17M | $117.8M | -$289.78M | -$427K | $288.95M | — | — | — | — |
| Working capital / revenue | +3.90% | +4.51% | -9.89% | -0.01% | +8.72% | — | — | — | — |
Sourced from key_metrics + financial_ratios (loaded by load_fundamentals_extended.py).
Valuation
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| P / E | — | — |
| P / B | — | — |
| EV / EBITDA | — | — |
| EV / Sales | 1.15x | 1.79x |
| Earnings yield | -85.7% | 7.0% |
| FCF yield | -34.2% | -15.4% |
Returns
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| ROE | -56.6% | 8.3% |
| ROA | -20.0% | 4.3% |
| ROIC | 7.7% | 7.4% |
Leverage & liquidity
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Debt / equity | — | — |
| Net debt / EBITDA | -3.42 | 3.31 |
| Interest coverage | — | — |
| Current ratio | 1.55x | 1.00x |
| Quick ratio | — | — |
Methodology. ROE / ROA / ROC use period-end balance-sheet denominators (no average-of- period smoothing). ROIC = Operating Income × (1 − inferred effective tax rate) over invested capital, with the effective tax inferred from net-to-operating income when both are positive and a 25% default otherwise. Net debt / EBITDA, debt ratios, and interest-coverage ratios are calculated point-in-time at each fiscal year-end. TTM = trailing 4 quarters (income / cash flow summed, balance sheet = most-recent quarterly snapshot). Through-cycle CAGR in the Growth panel uses the geometric mean of first-to-last period growth across the window (positive values only).